Clinical

People with muscle-specific kinase myasthenia gravis appear to have more active antibody responses in general, the study found.

Using a clustering algorithm, researchers were able to identify inflammatory and noninflammatory subsets of the disease, which may account for varying responses to certain treatments.

The researchers noted that their study is the first to assess the ability of noninvasive variables, both resting- and exercise-based, to identify pulmonary hypertension in interstitial lung disease.

A group of researchers detailed a case of acquired hemophilia A (AHA) following infection and again following vaccination, and provided additional insights through their systematic review of available data.

A new report found only about 2.8% of people with myelodysplastic syndromes (MDS) have JAK2 mutations.

The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.

A study of Navy sailors and Marines from the United States found that only 7.7% of participants had neutralizing antibodies for the Omicron variant 8 months after vaccination.

In the first keynote session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit, the history of CRISPR genome editing and its potential in cancer and other settings took center stage.

A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.

Drs Coney, Luo, and Sheth discuss potential novel treatment mechanisms or options that we could see in the future with wet AMD and DME.

The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.

Therapy adjustments in MDR HIV are explored by Dr Sension.

Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.

Patients with complex chronic disease can be grouped by varying propensity for health care continuity patterns, which could be harnessed to personalize health care utilization interventions.

The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.

The EASIX scoring system should not be used to predict outcomes following allogeneic stem cell transplantation (alloSCT) in patients with myelofibrosis.

This article examines the effect of a transplant case management program on clinical outcomes following transplant surgery.

Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.

Drs Michos and Baum provide payer considerations regarding HoFH treatment pathways.

Considerations for authorization documentation in HoFH treatment are discussed.

Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

The researchers used Paraphase on more than 400 samples of spinal muscular atrophy (SMA) comprising 5 ethnicities.

The risk of death among people with primary myelofibrosis (PMF) dropped by 53% after ruxolitinib’s introduction, the study found, although the data also suggested only 8.5% of patients were prescribed the drug.

Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.